VEPESID Drug Patent Profile

Which patents cover Vepesid, and what generic alternatives are available?

Vepesid is a drug marketed by Strides Pharma and Corden Pharma and is included in two NDAs.

The generic ingredient in VEPESID is etoposide. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the etoposide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vepesid

A generic version of VEPESID was approved as etoposide by HIKMA on July 17^th, 1995.

Summary for VEPESID

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	230
Patent Applications:	2,711
DailyMed Link:	VEPESID at DailyMed

Recent Clinical Trials for VEPESID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RenJi Hospital	Phase 2
Incyte Corporation	Phase 2
Joseph Tuscano	Phase 2

See all VEPESID clinical trials

US Patents and Regulatory Information for VEPESID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-001	Dec 30, 1986		DISCN	Yes	No
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-002	Dec 30, 1986		DISCN	Yes	No
Corden Pharma	VEPESID	etoposide	INJECTABLE;INJECTION	018768-001	Nov 10, 1983		DISCN	Yes	No

Expired US Patents for VEPESID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-001	Dec 30, 1986
Corden Pharma	VEPESID	etoposide	INJECTABLE;INJECTION	018768-001	Nov 10, 1983
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-002	Dec 30, 1986

International Patents for VEPESID

See the table below for patents covering VEPESID around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	327416
African Intellectual Property Organization (OAPI)	2258
Switzerland	459255	Verfahren zur Herstellung von neuen 4'-Demethyl-epipodophyllotoxin-halogeniden
Netherlands	6613143
Switzerland	459257	Verfahren zur Herstellung von 4'-Demethyl-epipodophyllotoxin
Austria	281300
Germany	1543874

VEPESID Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Vepesid (Etoposide)

Introduction to Vepesid (Etoposide)

Vepesid, known generically as etoposide, is a potent anticancer medication used in the treatment of various types of cancer, including testicular cancer, lung cancer, ovarian cancer, and blood cancers such as Hodgkin's and non-Hodgkin's lymphoma, and acute myeloid leukemia[4].

Market Size and Growth

The global etoposide market was valued at US$ 715.62 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2030, reaching approximately US$ 1.061 billion by the end of the forecast period[1].

Key Drivers of Market Growth

Increasing Prevalence of Cancer

One of the primary drivers of the etoposide market is the growing prevalence of cancers, particularly prostate cancer. According to Globocan 2021 data, prostate cancer is the second most common type of cancer among men, with 1.4 million cases globally, accounting for 7.2% of all malignant tumors. The aging population, which is more prone to prostate cancer, is expected to further drive the market growth[1].

Regional Demand

North America, especially the United States and Canada, is anticipated to hold a significant market share due to the rising frequency of prostate cancer, increased awareness, and extensive research and development activities in the region. The American Cancer Society estimates that approximately 265,000 new prostate cancer cases will be diagnosed in the United States in 2023, with a high incidence among men aged 64 and older[1].

Market Segmentation

By Form

Etoposide is available in two primary forms: injection and oral capsules. The oral form is particularly convenient for patients, as it can be taken on an empty stomach, although the dose is adjusted to be comparable to the intravenous form[4].

By Application

The market is segmented by application into several cancer types, including small cell lung cancer, testicular cancer, and non-epithelial ovarian cancer. The small cell lung cancer segment is expected to grow at a CAGR of 3.8% during the forecast period, highlighting the drug's continued importance in treating this aggressive form of lung cancer[1].

Financial Trajectory

Revenue Projections

The total revenue of the etoposide market is expected to increase significantly, driven by the growing demand for cancer treatments. The market's CAGR of 5.8% indicates a steady and robust growth trajectory over the next several years[1].

Investment and R&D

Pharmaceutical companies and academic institutions are investing heavily in research and development, which is crucial for the growth of the etoposide market. Despite the high costs and long development timelines associated with bringing new drugs to market (averaging $2.6 billion and 10-15 years), the potential rewards for successful drugs are substantial, making continued investment in cancer research a priority[3].

Regulatory Environment

Harmonization of Prescribing Information

The European Medicines Agency (EMA) has undertaken efforts to harmonize the prescribing information for Vepesid across the European Union. This includes standardizing the summaries of product characteristics (SmPCs), labeling, and package leaflets to ensure consistent use and safety across member states[4].

Challenges and Restraints

Adverse Effects and Safety Concerns

Etoposide is associated with several adverse effects, including low blood cell counts, nausea, lack of appetite, diarrhea, hair loss, and fever. More serious adverse reactions include hypotension and potential harm to the fetus if used during pregnancy. These safety concerns can impact patient compliance and overall market growth[1].

High Cost of Cancer Medications

The high cost of cancer medications, particularly those for lung cancer, is a significant restraint for new market entrants and can limit access to treatment for some patients[1].

Competitive Landscape

Key Players

Companies like Bristol-Myers Squibb, which markets Vepesid, play a crucial role in the etoposide market. The competitive landscape includes market leaders, followers, and new entrants, with ongoing research and development activities driving innovation and competition[1].

Regional Insights

North America

North America is expected to dominate the market due to the high incidence of prostate cancer and other cancers, along with advanced healthcare infrastructure and significant investments in cancer research[1].

Europe

Europe also represents a significant market, with Vepesid being marketed in 16 EU member states and Norway. The harmonization efforts by the EMA aim to streamline the use of Vepesid across these regions[4].

Asia Pacific

The Asia Pacific region is another key market, driven by the growing incidence of cancer and improving healthcare systems in countries like China, Japan, and India[1].

Conclusion

The etoposide market, driven by the increasing prevalence of cancers and significant investments in research and development, is poised for steady growth. Despite challenges such as adverse effects and high medication costs, the market is expected to reach nearly US$ 1.061 billion by 2030. Regulatory harmonization and continued innovation will be crucial in shaping the future of this market.

Key Takeaways

• The global etoposide market is valued at US$ 715.62 million in 2023 and is expected to grow at a CAGR of 5.8% until 2030.
• The primary driver of the market is the growing prevalence of prostate cancer and other cancers.
• North America is expected to hold a significant market share due to high cancer incidence and advanced healthcare infrastructure.
• Adverse effects and high medication costs are significant restraints.
• Regulatory harmonization efforts are underway to standardize the use of etoposide across different regions.

FAQs

What is the primary driver of the etoposide market?

The primary driver of the etoposide market is the growing prevalence of prostate cancer and other types of cancer.

Which region is expected to dominate the etoposide market?

North America, particularly the United States and Canada, is expected to hold a significant market share.

What are the common adverse effects of etoposide?

Common adverse effects include low blood cell counts, nausea, lack of appetite, diarrhea, hair loss, and fever. More serious adverse reactions include hypotension and potential harm to the fetus if used during pregnancy.

How is the etoposide market segmented?

The market is segmented by form (injection and oral) and by application (small cell lung cancer, testicular cancer, etc.).

What is the projected market size of etoposide by 2030?

The etoposide market is expected to reach nearly US$ 1.061 billion by 2030.

Sources

1. Maximize Market Research: Etoposide Market - Region and Forecast (2024-2030)
2. Novartis: Novartis 20-F 2014
3. DrugBank Blog: Investment Trends in Pharmaceutical Research
4. European Medicines Agency: Vepesid - referral